Olaparib research update: mechanism, structure and clinical trials

Abstract

Current cancer treatments are known for their low selectivity, and life-threatening toxicity. To solve these issue, various innovative approaches were applied. One of them is the inhibition of DNA repair mechanisms, which have been developed as a new hotspot for its selective inhibition and low toxicity. Notably, PARP inhibition has shown potential for effective targeted cancer therapy. Olaparib, the first FDA-approved PARP inhibitor, has been available for nearly a decade, demonstrating superior efficacy in treating breast and ovarian cancers. This article reviews the latest mechanistic studies, structural modifications, and clinical trials of Olaparib.